Nov 17 (Reuters) - Prometic Life Sciences Inc PLI.TO -
* Early evidence of efficacy of PBI-4050 alone and also in combination with one of commercially available IPF drugs
* PBI-4050 shown to be very well tolerated whether used alone or in combination with nintedanib or pirfenidone
* 4050 demonstrates early evidence of efficacy in its idiopathic pulmonary fibrosis ("IPF") phase 2 clinical trial Source text for Eikon: ID:nCNWNdvwpa Further company coverage: PLI.TO